即时焦点：大摩：将诺和诺德欧股目标价下调至300丹麦克朗

Group 1 - Morgan Stanley has lowered the target price for Novo Nordisk's stock from 380 Danish Krone to 300 Danish Krone, changing its rating from "Equal Weight" to "Underweight" [2] - East China Pharmaceutical (000963.SZ) has not engaged in any collaboration with Novo Nordisk regarding the semaglutide product [2] - Gan & Lee Pharmaceuticals (603087.SH) has no business cooperation with Eli Lilly and Novo Nordisk [2]